Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Down 19.6% in March

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 434,100 shares, a drop of 19.6% from the February 28th total of 539,600 shares. Based on an average trading volume of 1,420,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.6% of the shares of the stock are short sold.

Cyclo Therapeutics Stock Performance

Shares of CYTH stock opened at $0.72 on Tuesday. Cyclo Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.79. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $0.73. The firm has a market capitalization of $23.72 million, a price-to-earnings ratio of -0.80 and a beta of -0.57.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC purchased a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.15% of Cyclo Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.